{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:08:09Z","timestamp":1780304889481,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.transproceed.2025.07.024","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:08:53Z","timestamp":1756552133000},"page":"1635-1651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System(FAERS) Event for Belatacept"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8896-1967","authenticated-orcid":false,"given":"Chengze","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.transproceed.2025.07.024_bib0001","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.transproceed.2025.07.024_bib0002","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00007890-199801270-00018","article-title":"Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients","volume":"65","author":"Roth","year":"1998","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.transproceed.2025.07.024_bib0003","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/ajt.13698","article-title":"Effect of an early switch to belatacept among calcineurin inhibitor-intolerant graft recipients of kidneys from extended-criteria donors","volume":"16","author":"Le Meur","year":"2016","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.transproceed.2025.07.024_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12930","article-title":"Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients","volume":"31","author":"Wojciechowski","year":"2017","journal-title":"Clin Transpl"},{"issue":"9","key":"10.1016\/j.transproceed.2025.07.024_bib0005","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/TP.0000000000002192","article-title":"Conversion to belatacept in maintenance kidney transplant patients: a retrospective multicenter European study","volume":"102","author":"Darres","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13544","article-title":"Biopsy-proven T-cell mediated rejection after belatacept rescue conversion: a multicenter retrospective study","volume":"37","author":"Bertrand","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0007","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.transproceed.2025.07.024_bib0008","article-title":"Belatacept for kidney transplant recipients","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.transproceed.2025.07.024_bib0009","first-page":"374","article-title":"Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk","volume":"32","author":"Bestard","year":"2012","journal-title":"Nefrologia"},{"issue":"3","key":"10.1016\/j.transproceed.2025.07.024_bib0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2025.07.024_bib0011","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept","volume":"12","author":"Archdeacon","year":"2012","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.transproceed.2025.07.024_bib0012","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/ajt.12459","article-title":"Long-term exposure to belatacept in recipients of extended criteria donor kidneys","volume":"13","author":"Charpentier","year":"2013","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.transproceed.2025.07.024_bib0013","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients","volume":"90","author":"Griny\u00f3","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0014","doi-asserted-by":"crossref","first-page":"1558930","DOI":"10.3389\/fphar.2025.1558930","article-title":"Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.transproceed.2025.07.024_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40264-015-0388-3","article-title":"Performance of stratified and subgrouped disproportionality analyses in spontaneous databases","volume":"39","author":"Seabroke","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0016","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"issue":"04","key":"10.1016\/j.transproceed.2025.07.024_bib0017","first-page":"385","article-title":"Safety comparison of axitinib and everolimus in the treatment of renal cancer:analysis of adverse events based on pharmacovigilance database","volume":"11","author":"Chen","year":"2021","journal-title":"Anti-tumor Pharm"},{"issue":"07","key":"10.1016\/j.transproceed.2025.07.024_bib0018","first-page":"975","article-title":"Research on signal mining of adverse events of GLP-1 receptor agonists based on FAERS","volume":"41","author":"Yanxin","year":"2022","journal-title":"Her Med"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say","volume":"14","author":"Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.892503","article-title":"Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.transproceed.2025.07.024_bib0022","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.transproceed.2025.07.024_bib0033","unstructured":"NULOJIX (belatacept) [prescribing information]. Revised July 2021. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125288s0000lbl.pdf. Accessed July 28, 2021."},{"issue":"1","key":"10.1016\/j.transproceed.2025.07.024_bib0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.transproceed.2025.07.024_bib0024","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.transproceed.2025.07.024_bib0025","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/TP.0b013e3181ff87cd","article-title":"Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies","volume":"90","author":"Larsen","year":"2010","journal-title":"Transplantation"},{"issue":"26","key":"10.1016\/j.transproceed.2025.07.024_bib0027","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMc1602859","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Meaney","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.transproceed.2025.07.024_bib0026","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2025.07.024_bib0028","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2025.07.024_bib0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.07.024_bib0031","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaad.2019.09.070","article-title":"Belatacept reduces skin cancer risk in kidney transplant recipients","volume":"82","author":"Wang","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.transproceed.2025.07.024_bib0029","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.transproceed.2025.07.024_bib0034","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.ajt.2025.03.004","article-title":"Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients in the United States","volume":"25","author":"Ahmed","year":"2025","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.transproceed.2025.07.024_bib0035","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.transproceed.2025.07.024_bib0032","first-page":"607","article-title":"The enlightens on Ca rrying out reporting responsibility of manufactures in China from reviewing the post ma rketing surveillance system in US","volume":"14","author":"Dong","year":"2017","journal-title":"Chin J Pharmacovigil"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525003835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525003835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:38:03Z","timestamp":1780303083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134525003835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0041134525003835"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.07.024","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System(FAERS) Event for Belatacept","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}